Clinical trials: Death, Cardiac
Epilepsy, Seizures
Neural Circulatory Control and SUDEP Risk.
The investigators believe epilepsy alters the way the body controls blood pressure, heart rate and breathing, and these changes increase the risk of sudden unexpected death in patients with epilepsy (SUDEP).
- Trial name
- NC-SUDEP (NCT02813980)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Mayo Clinic
COVID-19, Myocarditis
Support for the Resumption of Training of High-level Athletes Post-epidemic COVID-19
As of March 2020, COVID-19 has become a global pandemic, halting athletic competition worldwide. Reports from China show a high prevalence of cardiac involvement in patients with severe SARS-CoV-2 infection.
- Trial name
- ASCCOVID19 (NCT04936503)
- Testing
- Resting electrocardiogram, Stress test, Cardiac echocardiography
- Where
- 21 sites in France
- Volunteers
- 984 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making
The goal of this research agenda is to improve the quality of end-of-life care by explicitly identifying values that will guide the decision-making process, with a particular emphasis on the role of ethnic, racial and cultural…
- Conditions
- Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Cirrhosis, Colon Carcinoma
- Trial name
- Aim3 (NCT00122135)
- Testing
- Values Inventory (VI)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- VA Office of Research and Development
Diabetes Mellitus Type 2, End Stage Renal Disease
Surrogate Markers for Sudden Cardiac Death in Patients With Diabetes Mellitus and End Stage Renal Disease
Aim: Patients with type 2 diabetes mellitus (T2DM) and hemodialysis due to diabetic nephropathy exhibit a high risk for sudden cardiac death (SCD).
- Trial name
- NCT02001480
- Testing
- 12 lead Holter, CGM Continuous Glucose Monitoring
- Where
- 3 sites in Germany
- Volunteers
- 60 people
- Sponsor
- RWTH Aachen University
Heart Failure
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one…
- Trial name
- Prevent-HF (NCT06677060)
- Testing
- Baxdrostat and dapagliflozin
- Where
- 977 sites in United States, Argentina and 33 more
- Volunteers
- 11,300 people
- Sponsor
- AstraZeneca